Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 |
Tel: | N/A |
Website: | https://larimartx.com |
IR: | See website |
Key People | ||
Carole S. Ben-Maimon President, Chief Executive Officer, Director | Michael Celano Chief Financial Officer, Company Secretary | Russell G. Clayton Chief Medical Officer | Gopi Shankar Chief Development Officer |
Business Overview |
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company's lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity. |
Financial Overview |
For the fiscal year ended 31 December 2023, Larimar Therapeutics Inc revenues was not reported. Net loss increased 5% to $36.9M. Higher net loss reflects Research and Development increase of 14% to $24.6M (expense), General and administrative increase of 13% to $9.6M (expense), Stock-based Compensation in SGA increase of 18% to $4.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.37 to -$0.84. |
Employees: | 42 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $325.36M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$41.38M as of Dec 31, 2023 |
Net annual income (TTM): | -$36.95M as of Dec 31, 2023 |
Free cash flow (TTM): | -$33.62M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 63,800,017 as of Mar 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |